<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362024</url>
  </required_header>
  <id_info>
    <org_study_id>0952-004</org_study_id>
    <secondary_id>2006_026</secondary_id>
    <nct_id>NCT00362024</nct_id>
  </id_info>
  <brief_title>MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)</brief_title>
  <official_title>MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of
      cognitive impairment in mild-to-moderate Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <enrollment type="Actual">24</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0952</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females

          -  Age &gt;/= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive,
             MHIS score &lt;/= 4, Global CDR score of 1 or 2

          -  Who have a reliable informant/caregiver to accompany patient to all clinic visits

          -  If using a symptomatic AD treatments, patients must be on stable dose for &gt;/= 6 months

        Exclusion Criteria:

          -  Patients must not be living in nursing home or skilled nursing facility

          -  Patients must not have current evidence and/or history of Crohn's disease, ulcerative
             colitis, proctitis, GI bleeding, mesenteric arteritis

          -  Patients must not have current evidence and/or history of poorly-controlled
             hypertension, clinically significant cardiac arrhythmia, angina, or CHF

          -  Patients must not have current evidence and/or history of a psychotic disorder or
             major untreated depressive disorder

          -  Patients must not have current evidence and/or history of stroke or multiple lacunar
             infarcts, or neurological or neurodegenerative disorder (other than AD)

          -  Various concomitant therapy restrictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2006</study_first_submitted>
  <study_first_submitted_qc>August 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2006</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

